Otsuka Pharmaceuticals blood oral tablet Inqovi approved by FDA

Inqovi is an oral tablet made up of the chemotherapy drugs Dixibin and cedazuridineCedazuridine is an approved DNA demethylator, and cedazuridine inhibits cytosine deaminase in the intestines and liver, avoiding degradation of the titamine, allowing Inqovi to be administered orallyClinical trialresults showed similar concentrations of drugs in patients compared to intravenous sitabins and oral InqoviIn addition, about half of patients who previously relied on blood transfusions no longer needed them for eight weeks of treatmentInqovi's safety characteristics are similar to those of the intravenous site of the Western TatabinThis innovative treatment option was previously qualified by the FDA for orphan medicine, and its listing application was also eligible for priority review"The FDA remains committed to providing patients with more treatment options during the COVID-19 pandemic." Today's approval provides an oral treatment option that can be administered at home, reducing the need for frequent patient visits to medical facilities," said DrRichard Pazdur, director of the FDA Center for Oncology Excellence and acting director of the FDA Center for Drug Evaluation and Research's Office of OncologyReferences:Fda Approves New Therapy for Myelodysplastic Syndromes (MDS) That Can Be Take at HomeRetrieved July 7, 2020, fromOriginal Title: Intravenous Intravenous To Or, FDA Approves New Treatment Options for Blood Cancer